Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.

ABSTRACT:

Background

Promoter mutation in the human telomerase reverse transcriptase gene (hTERT) occurs in ~75% of primary glioblastoma (GBM). Although the mutation appears to upregulate telomerase expression and contributes to the maintenance of telomere length, its clinical significance remains unclear.

Methods

We performed hTERT promoter genotyping on 303 isocitrate dehydrogenase 1 wild-type GBM tumors treated with standard chemoradiotherapy. We also stratified 190 GBM patients from the database of The Cancer Genome Atlas (TCGA) by hTERT gene expression. We analyzed overall and progression-free survival by Kaplan-Meier and Cox regression.

Results

We detected hTERT promoter mutation in 75% of the patients. When included as the only biomarker, hTERT mutation was not prognosti

SUBMITTER: Nguyen HN 

PROVIDER: S-EPMC5464302 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature